Yu J, Goldshtein I, Shalev V, Chodick G, Ish-Shalom S, Sharon O, Modi A
Merck & Co, Inc., Kenilworth, NJ, USA.
Medical Division, Maccabi Healthcare Services, Tel Aviv, Israel.
Int J Clin Pract. 2015 Sep;69(9):1007-14. doi: 10.1111/ijcp.12676. Epub 2015 Aug 17.
The objective was to examine the association of gastrointestinal (GI) events and osteoporosis treatment initiation patterns among postmenopausal women following an osteoporosis diagnosis from an Israeli health plan.
This retrospective analysis of claims records included women aged ≥ 55 years with ≥ 1 osteoporosis diagnosis (date of first diagnosis was index date). Osteoporosis treatment initiation was defined as use of osteoporosis therapy (oral bisphosphonates or other) during 12 months postindex. GI events (diagnosis of GI conditions) were reported for 12 months preindex and postindex (from index to treatment initiation or 1 year postindex, whichever occurred first). The association of postindex GI events (yes/no) with the initiation of osteoporosis treatment (yes/no) and with type of therapy initiated (oral bisphosphonate vs. other) were examined with logistic regression and Cox proportional hazard regression (as sensitivity analysis).
Among 30,788 eligible patients, 17.5% had preindex GI events and 13.0% had postindex GI events. About 70.6% of patients received no osteoporosis therapy within 1 year of diagnosis, 24.9% received oral bisphosphonates and 4.5% received other medications. Postindex GI events were associated with lower odds of osteoporosis medication initiation (85-86% reduced likelihood; p < 0.01). Upon treatment initiation, postindex GI was not significantly associated with the type of osteoporosis therapy initiated, controlling for baseline GI events and patient characteristics.
Among newly diagnosed osteoporotic women from a large Israeli health plan, 70.6% did not receive osteoporosis treatment within 1 year of diagnosis. The presence of GI events was associated with reduced likelihood of osteoporosis treatment initiation.
目的是研究以色列一项健康计划中绝经后女性骨质疏松症诊断后胃肠道(GI)事件与骨质疏松症治疗起始模式之间的关联。
这项对索赔记录的回顾性分析纳入了年龄≥55岁且有≥1次骨质疏松症诊断(首次诊断日期为索引日期)的女性。骨质疏松症治疗起始定义为在索引日期后12个月内使用骨质疏松症治疗药物(口服双膦酸盐或其他药物)。在索引日期前和索引日期后12个月(从索引日期到治疗起始或索引日期后1年,以先发生者为准)报告GI事件(GI疾病诊断)。通过逻辑回归和Cox比例风险回归(作为敏感性分析)研究索引日期后GI事件(是/否)与骨质疏松症治疗起始(是/否)以及起始治疗类型(口服双膦酸盐与其他药物)之间的关联。
在30788名符合条件的患者中,17.5%在索引日期前有GI事件,13.0%在索引日期后有GI事件。约70.6%的患者在诊断后1年内未接受骨质疏松症治疗,24.9%接受口服双膦酸盐治疗,4.5%接受其他药物治疗。索引日期后GI事件与骨质疏松症药物起始治疗的几率较低相关(可能性降低85 - 86%;p < 0.01)。在开始治疗时,在控制基线GI事件和患者特征的情况下,索引日期后GI与起始骨质疏松症治疗的类型无显著关联。
在以色列一项大型健康计划中新诊断为骨质疏松症的女性中,70.6%在诊断后1年内未接受骨质疏松症治疗。GI事件的存在与骨质疏松症治疗起始的可能性降低相关。